The Use of Alpha-Adrenergic Blockers as the Drug of Choice for Men with Symptomatic Benign Prostatic Hyperplasia
Author(s): HANAN M GARALLA, HANA ELBAKOUSH, HALIMA BOSHIHA, ISLAM ELAWAMI, KAMILAH ALMUGHRIBI, KHALED M DARRAZ
Background: Benign Prostatic Hyperplasia (BPH) is a common urological condition affecting older men, leading to Lower Urinary Tract Symptoms (LUTS). Alpha-1 adrenergic receptor blockers, such as tamsulosin, are commonly used to treat BPH-related LUTS.
Aim: This study aimed to evaluate the efficacy of oral tamsulosin in managing symptomatic benign prostatic hyperplasia (BPH) and improving urodynamic parameters in men aged ≥50 years while exploring the association between BPH, age, and comorbidities.
Methods: A retrospective analysis was conducted on 51 male patients aged ≥50 years diagnosed with symptomatic BPH and treated with tamsulosin (0.4 mg daily) from January 2021 to December 2023. Descriptive statistics were used to analyze patient demographics, comorbidities, and clinical parameters. Statistical significance was assessed using T-tests.
Results: The study found a significant positive correlation between age prostate size and PSA levels. Additionally, a higher prevalence of BPH was observed in patients with hypertension and diabetes. Tamsulosin treatment resulted in significant improvement in LUTS for 75% of the study participants. Moreover, 3 months of tamsulosin treatment, resulted in statistically significant improvements in peak voided volume (PVR) and maximum flow rate (Qmax) (p0.05).
Conclusion: This study demonstrates the effectiveness of tamsulosin in managing LUTS associated with BPH, with substantial improvements in PVR and Qmax. Age, hypertension, and diabetes were identified as significant risk factors for BPH. Further research is needed to explore the underlying mechanisms of BPH progression and to identify novel therapeutic strategies
View PDF